It is known that the 1.5-fold increase of beta-amyloid precursor protein (APP) dosage on chromosome 21 leads to typical AD symptoms and neuropathology already by the age of 40 years in most Down syndrome cases [23], so the triggers of any AD manifestation at ages 60–90 must be equivalent to an APP gene dosage much smaller than 1.5-fold. This evidence concerns the gene APP and Alzheimer disease.